Navigation Links
Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
Date:9/21/2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... London, New Delhi, Singapore and Washington DC (July 27, ... of Medical Decision Making , a large-scale, covert ... resources even with an extremely effective public health response, ... and initiating a response to it. The article ...
... 2009) An Italian research team, publishing in the ... is now available on-line without charge at http://www.ingentaconnect.com/content/cog/ct ... placenta may ultimately play a role in the treatment ... diseases caused by tuberculosis, chemical exposure, radiation or pathogens. ...
... Royal Holloway, University of London, has discovered evidence that ... frogs. The research, published in the August edition of ... about our long-tongued friends: wild frogs in the UK ... conducted her research with colleagues from the Institute of ...
Cached Biology News:Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2Placenta-derived stem cells may help sufferers of lung diseases 2Disease threat may change how frogs mate 2
(Date:11/22/2014)... -- The element of surprise has been a major advantage ... warning. Until now, epidemiologists had nothing to measure that ... in suboptimal responses to both the H1N1 pandemic of ... - http://photos.prnewswire.com/prnh/20141121/160242 That virus ... gene structural changes have been found that invariably to ...
(Date:11/21/2014)... TRU-D SmartUVC LLC and its UK partners, Rapid Disinfection ... TRU-D SmartUVC, at FIS 2014 in Harrogate, England ... Stand 23. The conference, hosted by Federation of ... largest infection-related event of its kind and brings together more ... events of its type throughout the world. This annual event ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 20, 2014 ... “A Short Walk to the Other Side” ... was an “Award-Winning Finalist in the “Fiction: Short Story” ... . , Jeffrey Keen, President and CEO of USA ... entries from mainstream and independent publishers, including Simon & ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3
... The 14th Annual National Ergonomics,Conference and Exposition (NECE) ... a record number of conference sessions, and mark ... geared toward workplace design,and occupational health professionals, as ... environments. These new tracks are coupled with,the NECE,s ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, today announced that its Senior Vice,President and ... a,company overview at the upcoming CIBC World Markets ... 2008 at 3:25 pm (eastern,time), at the Centre ...
... Shandong, China, Sept. 17 /Xinhua-PRNewswire-FirstCall/ --,China Biologic ... Biologic",or the "Company"), one of the leading ... China ("PRC"), today announced that the Company,received ... Drug Administration (the,"SFDA") to commence clinical trial ...
Cached Biology Technology:2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expo's 14-Year History 22008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expo's 14-Year History 3China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3